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Thedevelopmentofadversecardiovasculareventsdespiteaspirinusehasestablishedaninterestinapossibleresistancetothedrug.
Several deﬁnitions have been set and various laboratory testing modalities are available. This has led to a wide range of prevalence
reports in diﬀerent clinical entities. The etiologic mechanism has been related to clinical, genetic, and other miscellaneous factors.
The clinical implications of this phenomenon are signiﬁcant and warrant concern. Management strategies are currently limited
to dosing alteration and introduction of other anitplatelet agents. However, these measures have not met the expected eﬃcacy or
safety.
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1.Introduction
Despite the development of newer antiplatelet drugs in the
last decade, aspirin is still the most widely used antiplatelet
agent across the world to prevent cardiovascular diseases [1–
4]. In the 19th century, willow leaves became an attraction
after their extract, salicylic acid, was found eﬀective as an
analgesicforarthralgiasandanantirheumatic foravarietyof
rheumatic disease [5–7]. At the end of the 19th century the
acetylated form of salicylic acid was manufactured [8], with
less gastrointestinal side eﬀects, and consequently became
more widespread and commonly used. Long-term aspirin
administration in patients at high risk of occlusive vascular
events reduced up to 34% of nonfatal myocardial infarction
(MI), 25% of nonfatal stroke, and 18% of all-cause mortality
[4]. Ever since, several patients have reported developing
adverse vascular events despite aspirin intake, an observation
that was later coined the term “aspirin resistance” (AR)
[9]. Nowadays, the term has been employed to express the
occurrence of cardiovascular events in spite of regular intake
of aspirin at recommended doses [10–13]. Recent advances
in evaluating platelet function and the introduction of the
point-of-careplateletfunctionmachinerymadeassessingthe
degreeofplateletresponsetoacertainantiplateletdrugmore
reasonable, accessible, and easier to perform [14].
In this paper, the prevalence, mechanism, and clini-
cal implications of aspirin resistance will be highlighted.
Moreover, the available laboratory tests used to assess this
phenomenon and the possible ways to overcome it will be
described.
2.Terminology
The lack of agreement on a standardized deﬁnition for
“aspirin resistance” has contributed to the disparity in
reports of its incidence among diﬀerent studies. Whereas
some use the term “aspirin treatment failure,” while others
like to call it “aspirin nonresponsiveness.” The term “resis-
tance” was assigned based on biochemical and laboratory
ﬁndings in which aspirin was unable to inhibit one of the
many available in vitro tests of platelet function [15, 16].
Hence, from a pharmacologic point of view, resistance to
aspirin may be deﬁned as lack of ability to attain the
expected inhibition of platelet cyclooxygenase-(COX-)1 with
avoidance of platelet thromboxane (TX) A2 formation [17].
“Aspirin treatment failure” is deﬁned based on clinical
outcomes, when aspirin fails to prevent recurrent vascular
ischemicevents.However,reinfarctionafteraspirinuseinthe
setting of an acute coronary event may be due to thrombus
spread mediated by adenosine diphosphate (ADP) rather2 Advances in Hematology
Table 1: Prevalence of aspirin resistance.
Reference Patients Test used
Prevalence of AR
Comments
N(%)
Christiaens et al. [32] N = 97 PFA-100 analyzer 29 (29.9) ♀ > ♂ (38 versus 15%)
Stable CAD patients
already on aspirin
No clinical correlation with laboratory
parameters after 2.5 years follow-up
Pamukcu et al. [33] N = 234 PFA-100 analyzer 52 (22.2) Similar risk in resistant and nonresistant patients
after 20.6 ±6.9 months follow-up. Risk in aspirin
resistant patients increased after cessation of
clopidogrel
Stable CAD
Pamukcu et al. [34] N = 105 PFA-100 analyzer 20 (19) Greater risk of MACE in patients resistant to
aspirin
ACS
Akay et al. [35] N = 280 Optical platelet
aggregometry
77 (27.5) Large trial evaluating the frequency of AR in
healthy subjects
Healthy Turkish volunteers (ADP, AA)
Lee et al. [36] N = 468 VerifyNow-Aspirin 128 (27.4) 100mg or less daily dose were associated with a
higher incidence of AR in patients with CAD Stable CAD
Harrison et al. [30] N = 100 PFA-100 22 (22) Poor agreement between the diﬀerent tests leads
to the conclusion that aspirin resistance is highly
test-speciﬁc
Patients after TIA or Stroke VerifyNow-Aspirin 17 (17)
Optical platelet
aggregometry
5( 5 )
Gum et al. [28] N = 325 Optical platelet
aggregometry
18 (5.5) Trend toward increased age in patients with AR
Stable CAD PFA-100 analyzer 31 (9.5)
AR: aspirin resistance; CAD: coronary artery disease; ACS: acute coronary syndrome; MACE: major adverse cardicac events; ADP: adenosine diphosphate;
AA: arachidonic acid; TIA: transient ischemic attack.
than continuing TX-induced platelet aggregation; which
may render the terminology “failure” improper [18]. Some
suggested that until the various possible reasons of treatment
failure with aspirin have been recognized, the more suitable
term may be “aspirin nonresponsiveness” [15].
3.How PrevalentIsAspirinResistance?
Due to the lack of standardized testing for AR, prevalence
rates of nonresponders to aspirin among adults diﬀer
according to the platelet function test used and the threshold
of response, with a wide range reported (5.5 to 60%) [19–
22]. For instance, there are up to seven diﬀerent thresholds
for deﬁning aspirin response using the PFA-100 [23–29].
When using the combination of diﬀerent laboratory tests to
deﬁne resistance (VerifyNow-Aspirin, optical aggregometry,
and PFA-100), a lower resistance rate (2%) was reported as
compared to using each test alone [30].
The majority of studies on AR were conducted on adult
patients, but recently the prevalence of AR was studied in
44 children aged 1 to 17 years taking aspirin for diﬀerent
indications, by using diﬀerent laboratory tests. Six out of
44 were considered aspirin resistant according to at least
one laboratory test (5 by PFA-100, 1 by aggregometry, and
urinary 11dhTxB2), which leads to the conclusion that, as
with adults, the incidence of AR is also assay-dependent
in the pediatric population [31]. Table 1 summarizes the
main studies investigating AR prevalence in diﬀerent clinical
entities [28, 30, 32–36].
4.ProposedEtiology
4.1. Pharmacology of Aspirin. Low-dose aspirin (as low as
81mg) irreversibly inhibits the COX-1 enzyme, by acetylat-
ing the serine residue at position 529, consequently impair-
ing the transformation of arachidonic acid to prostaglandin
(G2/H2), and TX A2, which is a potent mediator of platelet
aggregation and activation. This eﬀect explains the clinical
beneﬁt of aspirin in patients with high risk vascular disease
[37–39]. Aspirin’s eﬀect on COX-2 is minimal in doses
<1200mg [40, 41].
4.2. Mechanism of Resistance. The diﬀerent mechanisms by
which AR might take place are not yet well understood
[10, 12, 13, 19]. Medication compliance is one preventable
and important contributor to the phenomenon of resistanceAdvances in Hematology 3
Clinical factors:
1. Diabetes
2. Heart failure
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Figure 1: Proposed factors contributing to aspirin resistance (CABG: coronary artery bypass grafting; COX: cyclooxygenase; NSAIDS:
nonsteroidal anti-inﬂamatory drugs; PPI: proton pump inhibitors).
and to the overreporting of aspirin nonresponsiveness [42].
To stress the importance of this factor, a recent meta-analysis
including 50000 patients at high risk of ischemic coronary
disease found that noncompliance or early discontinuation
of the drug carried a 3 times higher risk of cardiac events
(odds ratio [OR] 3.14, 95% conﬁdence interval [CI] 1.75–
5.61; P = .0001) [43]. Thus, explaining the beneﬁts of
antiplatelet therapy to the patient may help improving
compliance [44].
Some drugs may compete with aspirin at the COX-1
receptor site; of those, the most commonly encountered
are nonsteroidal anti-inﬂammatory drugs such as ibuprofen
which can oﬀset the clinical beneﬁt of aspirin in a variety
of vascular diseases [45]. The bioavailability of a drug
is dependent on numerous factors, absorption being the
most relevant. Lower doses of acetylsalicylic acid may be
hydrolyzed to a higher extent into an inactive form, by
gastrointestinal mucosal esterases when given with proton
pump inhibitors due to acid suppression, thus reducing the
absorption of the active drug. However, current evidence
failed to conﬁrm this argument [46, 47].
Another hypothesis considers resistance at the target site
of the drug’s action. This may highlight the role of genetic
studies to determine the potential contribution of some
genetic polymorphisms in AR. Polymorphisms in the COX-
1 gene have been implicated in the partial nonresponse to
low-dose aspirin [48, 49]. However, a recent large systematic
review addressing the role of diﬀerent genetic polymor-
phisms did not ﬁnd a clear association between COX-1 gene
polymorphisms (speciﬁcally C50T/A842G polymorphism)
andAR[50].Anothermajorgeneticcontributortobiological
AR is thought to be the PlA1/A2 polymorphism in the
GPIIIa platelet receptor [51–53], which is according to the
same systematic review, the most frequently investigated
parameter (19 studies involving 1389 subjects) [50]. This
variant was noticeably associated with AR when measured
in the healthy population (OR 2.36, 95% CI 1.24–4.49;
P = .009), but combining data from both healthy individuals
and those with cardiovascular disease reduced the size of
the observed eﬀect (OR 1.14, 95% CI 0.84–1.54; P = .40)
[50].
Poor glucose control and body weight are also proposed
to contribute to AR, where in a recent study assessing 48
patients with type 2 diabetes mellitus using the PFA-100
assay, AR was signiﬁcantly associated with HbA1c ≥8% (P =
.002) and obesity (BMI ≥ 30 kg/m2; P = .01) [54]. Although
this might implicate that better glucose control leads to less
incidence of AR, the clinical signiﬁcance of such ﬁndings
should be carefully inspected, since in two of the largest trials
[55, 56] assessing the role of aspirin on primary prevention
of cardiovascular events in patients with type2 diabetes, low-
doseaspirindidnotdecreasetheriskofcardiovascularevents
when compared to placebo (13.6 per 1000 person-year in
the aspirin group versus 17.0 per 1000 person-year in the
placebo group, hazard ratio [HR] 0.80; 95% CI 0.58–1.10 in
the JPAD trial [55]; 116 of 638 primary events in the aspirin
group compared with 117 of 638 in the no aspirin group,
HR 0.98; 95% CI 0.76–1.26 in the POPADAD trial [56]).
In the JPAD trial both groups (aspirin versus no aspirin)
had similar baseline characteristics in terms of glycosylated
hemoglobin (7.0 versus 7.1, resp.). On the other hand, the
aspirin group in the POPADAD trial had a mean HbA1c of
8.0 compared to 7.9 in the no aspirin group. The lack of
beneﬁcial eﬀect of aspirin in the latter study may be partly
explained by the fact that AR is signiﬁcantly associated with
HbA1c levels ≥8% [54].
Finally in all conditions associated with a high platelet
turnover (coronary artery bypass grafting, acute coronary
syndrome (ACS), acute or chronic infection, or inﬂamma-
tion), low-dose aspirin is associated with a short half-life (15
to 20 minutes) and might not be able to suppress COX-1
in fresh platelets that are continuously and quickly released
into the circulation in such stressful circumstances, leading
to higher platelet reactivity (Figure 1)[ 57–60].4 Advances in Hematology
5.Platelet-FunctionTesting
Multiple assays for platelet function and response to aspirin
have emerged in the past decade. The test that is considered
gold standard for assessment of the degree of aspirin
response is light transmittance aggregometry (LTA) [61].
This assay measures the increase in light transmittance
across platelet-rich plasma as a consequence of aggregation
o fp l a t e l e t sa n dd e v e l o p m e n to fc l u m p si nr e s p o n s et o
diﬀerent agonists (ADP, collagen, arachidonic acid). Several
drawbacks limit the use of this assay. However, it has been
described as time consuming, operator dependent, and of
high cost. Inability to reproduce results, even in the same
laboratory, has also been reported [62]. According to this
assay, the most accepted deﬁnition of AR is ≥20% platelet
aggregation with 1mg/mL arachidonic acid and ≥70%
aggregation with 10μmol/l ADP despite regular intake of
aspirin [63].
The point-of-care platelet function analyzer PFA-100
device (Dade Behring, Leiderbach, Germany) acts like an
injuredartery,wherehighshearstressconditionsarepresent,
and works in the presence of erythrocytes; unlike LTA where
there is no interaction between platelet and other blood
components. Hence, platelet function is evaluated by the
timeneededtoformaplateletplugtooccludethegappresent
in this device. Using this test, AR is generally deﬁned as a
closure time of <164s despite regular aspirin intake. The
device is easy to use and requires only a small amount of
blood. The test is also fast and reproducible. Unfortunately,
correlation between clinical outcomes with the PFA-100 is
poor [64]. The lack of correlation with clinical outcome was
also demonstrated in a recent prospective study assessing the
prevalence of resistance in 97 patients with stable coronary
artery disease on 160mg aspirin for at least one month
using the PFA-100 and a follow-up of 2.5 years for the
composite of death, MI, and ischemic cerebral infarction
or acute limb ischemia. It was found that aspirin resistant
patients (29.9%) did not have a higher risk of death, MI,
or ischemic vascular event compared with aspirin-sensitive
patients [65]. Moreover, the reliance upon hematocrit and
plasma von Willebrand factor, along with high cost, limits
the use of PFA-100.
Another point-of-care newly introduced assay is the
VerifyNow-Aspirin (the Ultegra Rapid Platelet Function
Assay, Accumetrics Inc., San Diego, Calif, USA) which corre-
lateswellwithlighttransmittanceaggregometry[66].Results
from the VerifyNow-Aspirin were highly reproducible in
21 healthy volunteers and 40 patients with stable coronary
artery disease [67]. It also showed poor sensitivity and good
speciﬁcity with a cut-oﬀ value at 550 aspirin reaction units
(ARU), compared to LTA, which makes the signiﬁcance of
the cut-oﬀ level at 550 ARU for detecting AR controversial
[67].
Other test measures consider the end products of the
TX A2 pathway such as serum TX B2 [68], or urine 11-
dehydroTX B2 [49], for assessing aspirin activity [49]. In
fact, these two tests may better reﬂect the amount of
TX A2 derived from sources other than platelets such as
macrophages and monocytes, and on the COX-2 linked
pathway of arachidonic acid, which is blocked by aspirin
at very high doses (1200mg) only [40, 41]. Urinary 11-
dehydroTX B2 concentration is aﬀected by kidneys pro-
duction of this substance; however, measurement of this
metabolite is still commonly used in trials assessing AR due
to its low cost and ease to carry out [49, 69].
A relevant question is the extent to which these lab-
oratory methods correlate with one another. The various
laboratory assays used to identify AR are compared weakly
with each other. This was demonstrated in a study using
six diﬀerent platelet function tests in 201 patients with
stable coronary artery disease who were on daily aspirin use.
The encounter of AR varied according to the assay used,
being uppermost for the PFA-100 (60%) and lowermost
using LTA (4%) [70]. Workup of a patient with suspected
aspirin resistance, eventually leading to appropriate platelet-
function testing, is highlighted in Figure 2.
6. ClinicalImplication
Another signiﬁcant question to consider is whether this
phenomenon is conﬁned to laboratory ﬁndings or aﬀects the
expected clinical outcome. A recent meta-analysis on 2930
patients with cardiovascular disease, who were on aspirin
(75–325mg daily) alone or in combination with other
antiplatelet therapy, found resistance to be more prevalent in
females as well as in patients with renal impairment. These
populations were found to carry a fourfold higher risk of
death due to vascular events and higher risk of nonfatal cere-
brovascular and cardiovascular events compared to aspirin
sensitive patients (39% of AR patients versus 16% of aspirin
sensitive patients had a cardiovascular event, OR 3.85, 95%
CI 3.08–4.80; P<. 001), regardless of the assay used to assess
resistance [71]. The authors conclusions are reinforced by
a previous meta-analysis evaluating clinical outcome in AR,
where again, resistant patients had considerably higher risk
of recurrent vascular events compared to aspirin sensitive
patients [72].
In a recent trial evaluating the relationship between AR
(assessed by thrombelastography) and stroke in 45 patients
withischemicstroke,itwasfoundthatARwasmorefrequent
in the stroke than the control arm (67% versus 40%; P =
.028). Within the stroke group, the AR arm had more severe
stroke(assessedby Rankin score).In addition AR wasgreater
in lacunar than embolic strokes [73]. In a follow-up of 468
patients with stable coronary artery disease and/or a high
risk for vascular events (diabetic and/or hypertensive) for a
mean period of 379 ± 200 days, cardiovascular death and/or
nonfatal events were more frequent among patients with AR
[74]. Moreover, after measuring urinary 11-dehydroTX B2
levels in 976 high-risk patients (half of them had sustained
previous vascular events) who were initially enrolled in
the heart outcomes prevention evaluation (HOPE) trial
(on aspirin for 5 years), it was demonstrated that patients
with levels in the highest quartile sustained more MI and
cardiovascular death versus those in the lowest quartile [49],
the drawbacks of this nested case control study were the issue
of compliance which was not veriﬁed adequately by objective
laboratory methods.Advances in Hematology 5
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Figure 2: Algorithm highlighting approach to a patient with suspected aspirin resistance. ACS: acute coronary syndrome; NSAIDs:
nonsteroidal antiinﬂamatory drugs; PPI: proton pump inhibitors; CAD: coronary artery disease; MI: myocardial infarction; PVD: peripheral
vascular disease; LTA: light transmittance aggregometry; PFA: platelet function analyzer.
The clinical correlation of AR was also elucidated in
patients undergoing percutaneous coronary intervention
(PCI) in a recent study that measured the cardiac biomarkers
(CK-MB and Troponin I) in 151 patients who underwent
nonurgent PCI and who were already on various doses
of aspirin and a 300mg loading dose of clopidogrel. The
study demonstrated that patients with AR, assessed using
the VerifyNow-Aspirin test, sustained a considerably higher
incidence of post-PCI elevation in cardiac biomarkers [75].
Furthermore, in 216 patients with ST elevation myocardial
infarction (STEMI), enhanced platelet activity assessed with
PFA-100,wasanindependentpredictorofmarkersofcardiac
necrosis [76]. The laboratory response to glycoprotein (GP)
IIB/IIIA inhibitors and the clinical outcome in 70 patients
with STEMI undergoing PCI correlated well with baseline
platelet reactivity (PR) (assessed with the PFA-100) before
intervention. High-baseline PR was associated with a 5–11
times increase in the risk of death, reinfarction, and target
vessel revascularization (HR 11, 95% CI 1.5–78; P = .02
when the PFA-100 was used and HR 5.2, 95% CI 1.1–23;
P = .03 using the LTA) [77].
Finally, aspirin resistance has been implicated recently as
a potential cause of the rare but very serious complication
of drug eluting stents thrombosis. This was demonstrated in
a prospective systematic analysis of platelet aggregation in
four subsequent cases of late thrombosis, where all four cases
showed resistance to either aspirin (evaluated with the PFA-
100) or clopidogrel, and two cases showed dual resistance to
both of these platelet antiaggregants [78].
7. Management
After correlating AR with incidence of more adverse car-
diovascular events many investigators are trying to ﬁnd
solutions to overcome this poor response. The idea of
increasing aspirin dose in order to overcome resistance
has been assayed in many studies, since there is some
evidence that response to aspirin may be dose-dependent6 Advances in Hematology
[27]. Laboratory and genetic inconsistency as well as dose
dependence is seen when agonists other than arachidonic
acid (the most speciﬁc in assessing AR), such as (ADP,
collagen, epinephrine), are used for in vitro assessment of
platelet inhibition by aspirin. This inconsistency and dose-
dependence may be explained by the fact that those agonists
maybe only in part reliant upon, or even independent of, the
COX-1 pathway which is the main target of aspirin [79–82].
More solid evidence that reﬂects on the appropriate dosage
of aspirin was portrayed by the antithrombotic trialists
collaboration. It showed that the most eﬀective aspirin dose
with the fewest adverse consequences is 75 to 150mg once
daily with similar eﬃcacy as doses up to 1500mg daily
[8, 83]. Even though low-aspirin doses might relate to
resistance by reducing absorption, administration of higher
doses looks unwarranted and is outweighed by a higher risk
of gastrointestinal bleeding [84].
In a number of studies, sensitivity of platelets to ADP
and levels of this agonist in patients with AR revealed
to be considerably ampliﬁed [25, 85]. Moreover, in a
randomized cross-over trial, patients with AR turned out
to be highly responsive to platelet ADP receptor antagonist
[86]. One could argue, based on the above that replacing
or adding a diﬀerent antiplatelet could cancel out the
incidence of adverse events resulting from resistance to
aspirin. This theory was refuted by a recent meta-analysis of
20 studies (6 of them had an additional antiplatelet used)
which found that concomitant treatment with additional
antiplatelet (namely, clopidogrel or tiroﬁban) provided no
clinical beneﬁt to those patients identiﬁed as aspirin resistant
(OR 2.52, 95% CI 1.79–3.56 for aspirin alone versus OR
3.06, 95% CI 1.99 to 4.70 for the dual antiplatelet group)
[71].Toelaborateontheissueofdualantiplatelet therapy,an
analysis of asymptomatic low-risk patients on both aspirin
and clopidogrel in the CHARISMA trial revealed a higher
incidence of death due to cardiovascular disease [87], and
that dual antiplatelet therapy should be reserved for patients
with high risk for vascular events [88]. The addition of
dipyridamole to aspirin has also been subject to much
debate [4, 89, 90]. In a recent review involving 23019
patients with vascular disease [91], dipyridamole alone or in
combination with aspirin did not lessen the risk of vascular
death(relativerisk [RR]0.99, 95% CI 0.87–1.12), thoughthe
risk of vascular events was lowered (RR 0.88, 95% CI 0.8–
0.95).
In particular, dealing with some patients who develop
adverse vascular events (e.g., cerebrovascular accidents
(CVA) and ACS) despite being on aspirin remains chal-
lenging, and many questions persist without clear cut
answers. There is no clear evidence and no consensus yet
on whether using diﬀerent laboratory assays to detect aspirin
resistance would guide therapy in those patients, especially
after a recent report assessing AR status with PFA-100 in
129 patients with transient ischemic attack (TIA), stroke,
or vascular cognitive impairment failed to predict new
thrombotic events in patients found to be AR during mean
follow-up of 56 months, as new thrombotic events occurred
in 15.4% of AR patients and in 14.6% of those without
resistance (P = 1.00) [92].
Although the subgroup analysis of the CAPRIE trial
failed to show a signiﬁcant beneﬁcial eﬀect of clopidogrel
over aspirin in patients with history of recent stroke or MI
[93], the recommendations issued by the American Heart
Association/American Stroke Association (AHA/ASA) in
2006 on stroke prevention [94] supported initial antiplatelet
therapy with the combination of aspirin and extended-
release dipyridamole (ER-DP), 25mg/200mg twice a day
(aggrenox), rather than aspirin (Grade 2A evidence) or the
useofclopidogrelforthosenottreatedwithaggrenox(Grade
2B evidence) in patients with a history of noncardioembolic
stroke or TIA of atherothrombotic, lacunar (small vessel
occlusive type), or cryptogenic type. Hence, adding an addi-
tional antiplatelet such as (ER-DP) or substituting aspirin
by another potent antiplatelet (namely, clopidogrel) would
be a logical alternative to patients who develop CVA despite
using aspirin on a daily basis. The addition of clopidogrel to
aspirinforsecondarystrokepreventionhasfallenoutoffavor
since the combination of the two drugs does not oﬀer better
beneﬁt for stroke prevention than either drug alone but does
considerably amplify the risk of bleeding complications [95].
Unlike patients who develop stroke, those being on aspirin
and develop ACS (unstable angina and non-STEMI) would
beneﬁt from adding clopidogrel to aspirin as per the famous
CURE trial [96].
8. Conclusion
Aspirin resistance is a true phenomenon that needs to be fur-
ther elucidated. A single deﬁnition should be provided when
describing resistance or nonresponse to aspirin. Moreover,
consensus should be made about the optimal laboratory
method that allows objective assessment of response to
aspirin. These points, if achieved, may normalize the wide
range of prevalence reported among diﬀerent studies. The
correlation between AR and higher incidence of adverse
vascular events is established by a considerable number
of well-designed trials. On the other hand, despite the
absence of optimal methods to overcome this phenomenon
of resistance, physicians must emphasize on proper patients
compliance, as well as avoidance of potential drug-drug
interactions. Finally one should always keep in mind that
no single platelet activation pathway is responsible for all
thrombotic complications, and a single treatment strategy
directed against a speciﬁc receptor/target cannot overcome
all thrombotic complications.
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